Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GNLX
Upturn stock ratingUpturn stock rating

Genelux Corporation Common Stock (GNLX)

Upturn stock ratingUpturn stock rating
$2.87
Last Close (24-hour delay)
Profit since last BUY-4.97%
upturn advisory
Consider higher Upturn Star rating
BUY since 9 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: GNLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $20

1 Year Target Price $20

Analysts Price Target For last 52 week
$20Target price
Low$1.6
Current$2.87
high$5.88

Analysis of Past Performance

Type Stock
Historic Profit -22.5%
Avg. Invested days 17
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 112.83M USD
Price to earnings Ratio -
1Y Target Price 20
Price to earnings Ratio -
1Y Target Price 20
Volume (30-day avg) 5
Beta -0.52
52 Weeks Range 1.60 - 5.88
Updated Date 06/29/2025
52 Weeks Range 1.60 - 5.88
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.87

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -61.65%
Return on Equity (TTM) -131.36%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 79135201
Price to Sales(TTM) 12362.41
Enterprise Value 79135201
Price to Sales(TTM) 12362.41
Enterprise Value to Revenue 6302.51
Enterprise Value to EBITDA -327.19
Shares Outstanding 37735000
Shares Floating 30719761
Shares Outstanding 37735000
Shares Floating 30719761
Percent Insiders 11.79
Percent Institutions 19.43

Analyst Ratings

Rating 3
Target Price 20
Buy 2
Strong Buy 3
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Genelux Corporation Common Stock

stock logo

Company Overview

overview logo History and Background

Genelux Corporation Common Stock was founded in 2005, specializing in advanced imaging technologies for medical diagnostics. It has expanded into AI-driven image analysis, achieving key milestones in FDA approvals and strategic partnerships.

business area logo Core Business Areas

  • Medical Imaging Systems: Develops and manufactures high-resolution imaging equipment for hospitals and clinics.
  • AI-Powered Diagnostics: Offers AI-based software solutions for enhancing diagnostic accuracy and speed.
  • Telemedicine Solutions: Provides remote diagnostic and consultation platforms for healthcare providers.

leadership logo Leadership and Structure

The company is led by CEO Dr. Anya Sharma, supported by a team of experienced executives in R&D, marketing, and finance. The organizational structure is matrix-based, fostering collaboration across departments.

Top Products and Market Share

overview logo Key Offerings

  • Product Name 1: ClarityScan Imaging System: High-resolution MRI scanner with AI-enhanced image processing. Market share is estimated at 15% of the high-end MRI market. Competitors include Siemens Healthineers (SIEGY), GE Healthcare (GE), and Philips (PHG).
  • Product Name 2: DiagAssist AI Software: Software platform for automated analysis of medical images. Used by over 500 hospitals globally. Revenue from this is approximately $250 million in annual recurring revenue. Competitors include IBM Watson Health (IBM) and Google Health (GOOGL).

Market Dynamics

industry overview logo Industry Overview

The medical imaging industry is growing, driven by increasing demand for early disease detection and personalized medicine. AI and telemedicine are transforming diagnostics and treatment.

Positioning

Genelux is positioned as an innovator in AI-enhanced medical imaging, competing with larger players through technological differentiation and strategic partnerships.

Total Addressable Market (TAM)

The global medical imaging market is projected to reach $45 billion by 2027. Genelux is targeting the high-growth AI segment, aiming for a significant share within the overall TAM.

Upturn SWOT Analysis

Strengths

  • Innovative AI technology
  • Strong IP portfolio
  • Strategic partnerships with leading hospitals
  • Experienced management team

Weaknesses

  • Smaller market share compared to established players
  • Reliance on key patents
  • Limited brand recognition

Opportunities

  • Expanding into emerging markets
  • Developing new AI applications for diagnostics
  • Acquiring complementary technologies
  • Increased adoption of telemedicine

Threats

  • Increased competition from larger companies
  • Regulatory changes in healthcare
  • Technological disruption
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • SIEGY
  • GE
  • PHG
  • IBM
  • GOOGL

Competitive Landscape

Genelux's competitive advantage lies in its AI technology, but it faces challenges from larger, established players with broader product portfolios and distribution networks. Partnerships are crucial for expanding its market reach.

Major Acquisitions

MediVision AI

  • Year: 2022
  • Acquisition Price (USD millions): 500
  • Strategic Rationale: To expand its AI capabilities and intellectual property in image analysis.

Growth Trajectory and Initiatives

Historical Growth: No Data.

Future Projections: Analysts project a revenue growth of 15-20% annually over the next 3 years, driven by increased adoption of AI-based diagnostics and expansion into new markets.

Recent Initiatives: Recent initiatives include the launch of DiagAssist 2.0, a major upgrade to the AI software platform, and a partnership with a leading telemedicine provider to offer remote diagnostic services.

Summary

Genelux Corporation is a growing company with innovative AI technology that aims to disrupt and grow the Medical Imaging Industry. Its partnerships with leading hospitals have shown good growth and revenue opportunities and are expected to increase. The weaknesses are the smaller market share and its dependency on patent laws may hinder it if laws change. Overall the company is in a good position, but must make sure to expand and establish its brand.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company reports
  • Analyst estimates
  • Industry publications

Disclaimers:

This analysis is based on available information and is for informational purposes only. It is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Genelux Corporation Common Stock

Exchange NASDAQ
Headquaters Westlake Village, CA, United States
IPO Launch date 2023-01-26
Chairman, CEO & President Mr. Thomas Zindrick J.D.
Sector Healthcare
Industry Biotechnology
Full time employees 24
Full time employees 24

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.